

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act  
of 1934 (Amendment No. \_\_\_\_)

Filed by the Registrant [ X ]

Filed by a Party other than the Registrant [ ]

Check the appropriate box:

Preliminary Proxy Statement

Confidential for Use of the Commission Only  
(as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to ss.240.14a-11(c) or ss.240.14a-12

Techne Corporation

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11

1) Title of each class of securities to which transaction applies:

2) Aggregate number of securities to which transaction applies:

3) Per unit price or other underlying value of transaction computed  
pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the  
filing fee is calculated and state how it was determined):

4) Proposed maximum aggregate value of transaction:

5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act  
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was  
paid previously. Identify the previous filing by registration statement  
number, or the Form or Schedule and the date of its filing:

1) Amount Previously Paid:

2) Form, Schedule or Registration Statement No.:

3) Filing Party:

4) Date Filed:

TECHNE CORPORATION

NOTICE OF ANNUAL MEETING OF SHAREHOLDERS  
to be held  
October 27, 2005

The annual meeting of shareholders of Techne Corporation (the "Company")  
will be held at the offices of the Company, 614 McKinley Place N.E.,  
Minneapolis, Minnesota, on Thursday, October 27, 2005, at 3:30 p.m. (Central  
Daylight Time), for the following purposes:

1. To set the number of members of the Board of Directors at six (6).
2. To elect directors of the Company for the ensuing year.

3. To take action upon any other business that may properly come before the meeting or any adjournment thereof.

Only shareholders of record shown on the books of the Company at the close of business on September 16, 2005 will be entitled to vote at the meeting or any adjournment thereof. Each shareholder is entitled to one vote per share on all matters to be voted on at the meeting.

You are cordially invited to attend the meeting. Whether or not you plan to attend the meeting, please sign, date and return your Proxy in the return envelope provided as soon as possible. Your cooperation in promptly signing and returning the Proxy will help avoid further solicitation expense to the Company.

This Notice, the Proxy Statement and the enclosed Proxy are sent to you by order of the Board of Directors.

THOMAS E. OLAND,  
President

Dated: September 27, 2005  
Minneapolis, Minnesota

TECHNE CORPORATION

PROXY STATEMENT  
for  
Annual Meeting of Shareholders  
to be held October 27, 2005

INTRODUCTION

Your Proxy is solicited by the Board of Directors of Techne Corporation (the "Company") for use at the Annual Meeting of Shareholders to be held on October 27, 2005 and at any adjournment thereof, for the purposes set forth in the attached Notice of Annual Meeting.

The cost of soliciting Proxies, including preparing, assembling and mailing the Proxies and soliciting material, will be borne by the Company. Directors, officers and regular employees of the Company may, without compensation other than their regular compensation, solicit Proxies personally or by telephone.

Proxies not revoked will be voted in accordance with the choice specified by shareholders by means of the ballot provided on the Proxy for that purpose. Proxies which are signed but which lack any such specification will, subject to the following, be voted in favor of the proposals set forth in the Notice of Meeting and in favor of the number and slate of directors proposed by the Nominating and Governance Committee of the Board of Directors and listed herein. If a shareholder abstains from voting as to any matter, then the shares held by such shareholder shall be deemed present at the meeting for purposes of determining a quorum and for purposes of calculating the vote with respect to such matter, but shall not be deemed to have been voted in favor of such matter. Abstentions, therefore, as to any proposal will have the same effect as votes against such proposal. If a broker returns a "non-vote" proxy, indicating a lack of voting instruction by the beneficial holder of the shares and a lack of discretionary authority on the part of the broker to vote on a particular matter, then the shares covered by such non-vote shall be deemed present at the meeting for purposes of determining a quorum but shall not be deemed to be represented at the meeting for purposes of calculating the vote required for approval of such matter.

The mailing address of the Company's principal executive office is 614

McKinley Place N.E., Minneapolis, MN 55413. The Company expects that this Proxy Statement and the related Proxy and Notice of Annual Meeting will first be mailed to shareholders on or about September 27, 2005.

#### OUTSTANDING SHARES AND VOTING RIGHTS

The Board of Directors of the Company has fixed September 16, 2005 as the record date for determining shareholders entitled to vote at the Annual Meeting. Persons who were not shareholders on such date will not be allowed to vote at the Annual Meeting. At the close of business on September 16, 2005, 38,864,314 shares of the Company's Common Stock were issued and outstanding. Such Common Stock is the only outstanding class of stock of the Company. Each share of Common Stock is entitled to one vote on each matter to be voted upon at the meeting. Holders of the Common Stock are not entitled to cumulative voting rights in the election of directors.

#### PRINCIPAL SHAREHOLDERS

The following table provides information concerning the only persons known to the Company to be the beneficial owners of more than 5% of the Company's outstanding Common Stock as of September 16, 2005:

Name and Address of Beneficial Owner	Amount and Nature of Shares Beneficially Owned(1)	Percent of Class(2)
Select Equity Group, Inc., Select Offshore Advisors, LLC and George S. Loening 380 Lafayette Street, 6th floor New York, NY 10003	2,906,666	7.5%
Barclays Global Investors, NA, Barclays Global Fund Advisors, Barclays Capital Securities Limited and Palomino Limited 45 Fremont Street San Francisco, CA 94105	2,387,857 (3)	6.1%
Thomas E. Oland 614 McKinley Place N.E. Minneapolis, MN 55413	1,742,569 (4)(5)	4.5%(4)

(1) Unless otherwise indicated, the person listed as the beneficial owner of the shares has sole voting and sole investment power over the shares.

(2) Shares not outstanding but deemed beneficially owned by virtue of the right of a person to acquire them as of September 16, 2005, or within sixty days of such date are treated as outstanding only when determining the percent owned by such individual and when determining the percent owned by the group.

(3) Sole voting power over 2,175,131 shares, no shared voting or investment power.

(4) Does not include 833,708 shares held by the Company's Stock Bonus Plan for accounts of employees other than Mr. Oland, which are included in the group total in the Management Shareholding table. The Company's Board of Directors, acting by a majority vote, currently directs the Trustee as to the voting of such shares. Including such 833,708 shares, Mr. Oland, a director of the Company, beneficially owns 2,576,277 shares or 6.6% of total shares outstanding plus shares subject to options exercisable by him.

(5) Includes 976,920 shares owned directly, 91,169 held by the Company's Stock Bonus Plan for Mr. Oland's account, 68,556 shares held by Thomas Oland and Associates, 205,924 shares held by the Thomas Oland and

Associates Profit Sharing Plan and Trust and 400,000 shares subject to stock options which are currently exercisable.

## MANAGEMENT SHAREHOLDINGS

The following table sets forth the number of shares of the Company's Common Stock beneficially owned as of September 16, 2005, by each executive officer of the Company named in the Summary Compensation Table, by each director and by all directors and executive officers (including the named individuals) as a group. Shares beneficially owned by Mr. Oland constitute 4.5% of total shares outstanding plus shares subject to options exercisable by him. Each other individual beneficially owns less than one percent of total shares outstanding plus shares subject to options exercisable by him or her. As a group, officers and directors beneficially own 8.2% of total shares outstanding plus shares subject to options exercisable by them.

2

Name of Director or Executive Officer Group	Number of Shares Beneficially Owned(1)
Thomas E. Oland	1,742,569 (2)(3)
Roger C. Lucas, Ph.D.	78,956 (4)(5)(6)
Howard V. O'Connell	186,080 (4)(6)(7)
G. Arthur Herbert	194,360 (4)(6)(8)
Monica Tsang, Ph.D.	131,864 (9)
Randolph C. Steer, M.D., Ph.D.	30,000 (4)(6)(10)
Marcel Veronneau	50,100 (11)
Robert V. Baumgartner	21,000 (4)(6)(12)
Gregory J. Melsen	426 (13)
Officers and directors as a group (10 persons)	3,186,609 (14)

- (1) Unless otherwise indicated, the person listed as the beneficial owner has sole voting and sole investment power over outstanding shares. Shares beneficially owned includes shares subject to options that are currently outstanding and exercisable and options that are currently outstanding and will become exercisable within 60 days of September 16, 2005.
- (2) See Note (3) to the preceding table.
- (3) See Note (4) to preceding table.
- (4) Does not include 924,877 shares held by the Company's Stock Bonus Plan, which are included in the total of officers and directors as a group. The Company's Board of Directors, acting by majority vote, currently directs the Trustee as to the voting of such shares.
- (5) Includes 20,000 shares owned by Dr. Lucas' wife and 37,500 shares subject to stock options.
- (6) Does not include an option to purchase 5,000 shares which will be granted on and will become exercisable as of the date of the Annual Meeting pursuant to the 1998 Nonqualified Stock Option Plan if the individual is reelected as a director of the Company.
- (7) Includes 136,080 shares owned by trusts of which Mr. O'Connell is a trustee and beneficiary and 50,000 shares subject to options.
- (8) Includes 11,000 owned by Mr. Herbert's wife, 153,360 shares held by trusts and partnership of which Mr. Herbert is a trustee or partner and 30,000 shares subject to options.
- (9) Includes 5,641 shares held by Dr. Tsang's husband, 38,721 and 37,598 shares held by the Company's Stock Bonus Plan for Dr. Tsang's and Dr. Tsang's husband's account and 3,612 shares subject to stock options.

- (10) Includes 30,000 shares subject to options.
- (11) Includes 6,135 shares held by the Company's Stock Bonus Plan for Mr. Veronneau's account and 15,019 shares subject to options.
- (12) Includes 20,000 shares subject to options.
- (13) Includes 426 shares subject to options.
- (14) Includes 924,877 shares held by the Company's Stock Bonus Plan as to which the Company's Board of Directors directs the voting and 586,557 shares which may be purchased pursuant to options.

3

ELECTION OF DIRECTORS  
(Proposals #1 and #2)

General Information

The Bylaws of the Company provide that the number of directors shall be determined by the shareholders at each annual meeting. The Nominations and Governance Committee of the Board of Directors of the Company recommends that the number of directors to be set at six and that the individuals named in the table below be elected. Under applicable Minnesota law and the Company's bylaws, approval of the proposal to set the number of directors at six, as well as the election of each nominee, requires the affirmative vote of the holders of the greater of (1) a majority of the voting power of the shares represented in person or by proxy at the Annual Meeting with authority to vote on such matter or (2) a majority of the voting power of the minimum number of shares that would constitute a quorum for the transaction of business at the Annual Meeting.

In the election of directors, each Proxy will be voted for each of the nominees listed below unless the Proxy withholds a vote for one or more of the nominees. Each person elected as a director shall serve for a term of one year or until his successor is duly elected and qualified. All of the nominees are members of the present Board of Directors. If any of the nominees should be unable to serve as a director by reason of death, incapacity or other unexpected occurrence, the Proxies solicited by the Board of Directors shall be voted by the proxy representatives for such substitute nominee as is selected by the Nominations and Governance Committee, or, in the absence of such selection, for such fewer number of directors as results from such death, incapacity or other unexpected occurrence.

The following table provides certain information with respect to the nominees for director.

Name	Current Position(s) Age with Company	Principle Occupation(s) During Past Five Years	Director Since
Thomas E. Oland	64	Chairman of the Board, Chairman of the Board, Chief Executive Officer, President, Treasurer and Director of the Company since 1985 and President of Research and Diagnostic Systems, Inc. since 1982.	1985
Roger C. Lucas, Ph.D.	62	Vice Chairman and Senior Scientific Advisor to the Company's Board and a private investor since 1995. Chief Scientific Officer, Executive Vice President and Secretary of the Company from 1985 to 1995.	1985
Howard V. O'Connell	75	Director Private investor since 1990. Chairman, President and	1985

Treasurer of John G. Kinnard and Company, Incorporated, a securities broker-dealer, from 1969 to 1990.

G. Arthur Herbert 79 Director Principal of CEO Advisors, 1989 a management and financial consulting firm, since 1989; from 1969 to 1988, President and Vice President Manager of Electro-Science Management Corp., a manager of venture capital partnerships.

4

Name	Age	Current	
		Position(s)	Director Since
-----			
Randolph C. Steer, M.D., Ph.D.	55	Director	1990
		Consultant to the pharmaceutical and biotechnology industries since 1989; Chairman (1999-2000) of Vicus.com, Inc.; Director of BioCryst Pharmaceuticals, Inc.	
Robert V. Baumgartner, C.P.A.	49	Director	2003
		Chief Executive Officer of Center for Diagnostic Imaging, Inc., an operator of diagnostic imaging centers, since 2001; CEO of American Coating Technologies, Inc., a manufacturer of coated paper, in 2000; CEO of First Solar, LLC, a producer of thin-film photo-voltaic coatings, in 1999 and 2000; from 1986 to 1999 various officer positions with Apogee Enterprises, Inc., a diversified manufacturer of glass and other products.	

#### Committees and Meetings of the Board of Directors

The Company's Board of Directors has three standing Committees, the Audit Committee, the Executive Compensation Committee and the Nominations and Governance Committee. All members of all Committees are "independent" as such term is defined in applicable law and regulations of the Securities and Exchange Commission and Nasdaq.

The Audit Committee (whose members are Messrs. Herbert, O'Connell and Baumgartner and Dr. Steer) operates under a written charter established by the Company's Board of Directors. The Audit Committee is responsible for the appointment and supervision of the Company's independent registered public accounting firm and for reviewing the Company's internal audit procedures, the quarterly and annual financial statements of the Company and the results of the annual audit. The Audit Committee also establishes and oversees the implementation of the Company's cash investment policy and monitors the Company's financial fraud hotline. The Board of Directors has determined that for fiscal 2005 all Audit Committee members are "audit committee financial experts" as such term is defined in Section 407 of the Sarbanes-Oxley Act. The Audit Committee met five times during fiscal 2005. The Committee's report is included in this Proxy Statement.

The Executive Compensation Committee (whose members are Dr. Steer and

Messrs. Herbert, O'Connell and Baumgartner) determines compensation for executive officers of the Company. The Committee met formally once during fiscal 2005. The Committee also had informal discussions related to compensation for several senior level positions within the Company which were filled during fiscal 2005. The Committee's report is included in this Proxy Statement.

5

The Nominations and Governance Committee is composed of all "independent" directors, currently all directors except Mr. Oland. The committee operates under a written charter. The functions of the Committee are to recruit well-qualified candidates for the Board, select persons to be proposed in the Company's proxy statement for election as directors at annual meetings of shareholders, and establish governance standards and procedures to support and enhance the performance and accountability of management and the Board. The Committee did not formally meet in fiscal 2005, however, it met informally and is conducting a search to replace the retired Dr. Christopher Henney. The Committee also determined to propose to shareholders at their 2005 annual meeting the re-election of the incumbent directors of the Company. The Committee will consider all nominees for director recommended by shareholders of the Company. Recommendations may be sent to the Committee at the Company's address: 614 McKinley Place N.E., Minneapolis, MN 55413. Candidates for the Board are considered and selected on the basis of outstanding achievement in their professional careers, experience, wisdom, personal and professional integrity, their ability to make independent, analytical inquiries, and their understanding of the business environment. Candidates must have the experience and skills necessary to understand the principal operational and functional objectives and plans of the Company, the results of operations and financial condition of the Company, and the position of the Company in its industry. Candidates must have a perspective that will enhance the Board's strategic discussions and be capable of and committed to devoting adequate time to Board duties.

During fiscal 2005, the Board held five meetings. Each director attended 75% or more of the total number of meetings of the Board and of Committees of which he was a member. Executive sessions of independent directors, meetings of outside directors without any member of management present, are held in conjunction with regularly scheduled meetings of the Board. It is the policy of the Company that all directors should attend the Company's annual meetings of shareholders. All members did attend the annual meeting in 2004.

#### Shareholder Communications with Directors

Shareholders may communicate directly with the Board of Directors. All communications should be directed to the Company at 614 McKinley Place N.E., Minneapolis, MN 55413, and should prominently indicate on the outside of the envelope that it is intended for the Board of Directors, for non-management directors, or for a particular director. Unless other distribution is specified, the communication will be forwarded to the entire Board. The communication will not be opened before being forwarded to the intended recipient, but it will go through normal security procedures.

#### Code of Ethics and Business Conduct and Financial Fraud Hotline

The Company has adopted a Code of Ethics and Business Conduct, which is applicable to all directors, officers and employees of the Company. A copy is available for review at the Company's website, [www.techne-corp.com](http://www.techne-corp.com). The Company sponsors a financial fraud hotline that is available to all employees, is operated on a confidential basis by a third party, and is supervised with full powers of investigation by the Audit Committee of the Board of Directors.

#### Directors' Fees

Directors who are not employees of the Company are compensated at the rate of \$25,000 per year for service on the Board and Committees of the Board. Directors are paid an additional \$1,000 for each meeting of the Board other than its regularly scheduled quarterly meetings and for each meeting of a committee on which the director serves other than committee meetings held in conjunction with a meeting of the full Board. Under the Company's 1998 Nonqualified Stock Option Plan, outside directors automatically receive an option to purchase shares of the Company's Common Stock on election and upon

each re-election. In connection with the 2005 Annual Meeting of Shareholders, the number of shares subject to the option granted to outside directors re-elected to the Board will be 5,000 per director.

## AUDIT MATTERS

### Audit Committee Report

The Audit Committee assists the Board of Directors with fulfilling its oversight responsibility regarding the quality and integrity of the accounting, auditing and financial reporting practices of the Company. In discharging its oversight responsibilities regarding the audit process, the Audit Committee:

- (1) reviewed and discussed the audited financial statements with management;
- (2) discussed with the independent registered public accounting firm the material required to be discussed by Statement on Auditing Standards No. 61; and

6

- (3) reviewed the written disclosures and the letter from the independent registered public accounting firm required by the Independence Standards Board's Standard No.1, and discussed with the independent registered public accounting firm any relationships that may impact their objectivity and independence.

Based upon the review and discussions referred to above, the Audit Committee recommended to the Board of Directors that the audited financial statements be included in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2005 as filed with the Securities and Exchange Commission.

Robert V. Baumgartner, C.P.A.  
G. Arthur Herbert  
Howard V. O'Connell  
Randolph C. Steer, M.D., Ph.D.  
Members of the Audit Committee

### Independent Registered Public Accountants

KPMG LLP acted as the Company's independent registered public accounting firm for fiscal 2005 and 2004. The appointment of an independent registered public accounting firm for the current fiscal year has not yet been made but will be made immediately following the 2005 annual meeting of shareholders. Representatives of KPMG LLP are expected to be present at the shareholders' meeting, will have the opportunity to make any desired comments, and will be available to respond to appropriate questions.

### Audit Fees

The following fees were paid or payable to KPMG LLP for the fiscal years ended June 30:

	2005	2004
	-----	-----
Audit Fees	\$440,640	\$125,700
Audit-Related Fees	\$ 21,525	\$ 37,500
Tax Fees	\$ 51,600	\$ 33,700
All Other Fees	\$ 63,000	\$157,000

"Audit Fees" are for professional services rendered and expenses incurred for the audit of the Company's annual financial statements and review of financial statements included in our Forms 10-K and 10-Q or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements. In 2005, audit fees also included fees incurred for the audits of management's assessment of the effectiveness of



internal controls over financial reporting and the effectiveness of internal control over financial reporting.

"Audit-Related Fees" in 2005 were primarily for services rendered and expenses incurred for the analysis of the Company's investments in entities in which the Company owns a minority interest and analysis of the Company's accelerated stock buyback transaction. "Audit-Related Fees" in 2004 were primarily for services rendered and expenses incurred for the analysis of the Company's investments in entities in which the Company owns a minority interest and advice on the Company's compliance with certain requirements of the Sarbanes-Oxley Act.

"Tax Fees" included fees for services provided and expenses incurred in connection with preparation of the Company's tax returns in the United States and the United Kingdom.

"All Other Fees" in 2005 and 2004 include fees for services and expenses incurred in connection with a claim for a refund of certain sales and use taxes paid to the State of Minnesota. Also included in 2005 were services and expenses incurred in connection with analysis of transfer pricing and repatriation of foreign earnings.

7

#### Pre-Approval Policies and Procedures

Pursuant to its written charter, the Audit Committee of the Company's Board of Directors is required to pre-approve the audit and non-audit services performed by the Company's independent registered public accounting firm in order to assure that the provision of such services does not impair the firm's independence. In 2005, the Audit Committee approved a resolution authorizing Company officers to engage KPMG in permitted non-audit services that involve less than \$25,000 in fees. Such services are reported to the Audit Committee and approved prior to completion of the audit. All of the services rendered by KPMG described above which were over \$25,000 were pre-approved by the Audit Committee. The Audit Committee has considered whether provision of the above non-audit services is compatible with maintaining KPMG's independence and has determined that such services have not adversely affected KPMG's independence.

## EXECUTIVE COMPENSATION

### Executive Compensation Committee Report

**Committee Interlocks and Insider Participation.** The Executive Compensation Committee of the Board of Directors of the Company is composed of directors G. Arthur Herbert, Howard V. O'Connell, Randolph C. Steer, M.D., Ph.D and Robert V. Baumgartner. None of the members of the Committee is or ever has been an employee or officer of the Company and none is affiliated with any entity other than the Company with which an executive officer of the Company is affiliated.

**Overview and Philosophy.** The Company's executive compensation program is comprised of base salaries, annual performance bonuses comprised of a cash and option component, long-term incentive compensation in the form of stock options, and various benefits, including the Company's profit sharing and savings plan and stock bonus plan in which all qualified employees of the Company participate. In addition, the Compensation Committee from time to time may award special cash bonuses or stock options related to non-recurring, extraordinary performance.

The Compensation Committee has followed a policy of paying annual base salaries which are on the moderate side of being competitive in its industry and of awarding bonuses based on achievement of specific revenue, profit and non-monetary goals. If the goals are achieved, the officer receives an option to purchase a number of shares with a fair market value on the date of grant equal to 20% of the officer's base salary and receives, at the election of the officer, either a cash bonus equal to 20% of the officer's base salary or an additional option to purchase a number of shares with a fair market value on date of grant equal to 170% of the cash bonus alternative. Bonuses are awarded on a prorated basis if between 85% and 100% of the specific

revenue and profit goals are achieved. The goals are established annually as recommended by the Chief Executive Officer of the Company and approved by the Compensation Committee.

The Company has formal employment agreements effective through June 30, 2007 with its full-time executive officers who served during fiscal 2005, other than its Chief Financial Officer whose employment agreement is effective through June 30, 2008 and Mr. Oland, its President, who serves pursuant to an oral understanding. See "Employment Contracts and Change in Control Arrangements" below. The agreements provide for base salaries subject to annual review, bonuses as described above, benefits as provided to all employees and severance compensation in the event that the officer's employment is terminated without cause or in connection with a sale or merger of the Company. With the exception of the Chief Financial Officer, severance compensation is dependent upon years of employment with or service to the Company. The Chief Financial Officer's severance compensation is equal to the base salary and benefits which would otherwise have been paid under the terms of the employment agreement or the base salary and benefits for twelve months from date of termination, whichever period is longer.

8

Compensation in 2005. During fiscal 2005, the Company maintained its principal compensation policies and made adjustments in base salaries to reflect competitive industry and individual performance factors. The Committee, at the beginning of fiscal 2005, established performance criteria for officers based 70% on growth in consolidated revenues and earnings and, working through the Company's Chief Executive Officer, 30% on individual goals which, if met, would permit each officer to earn a cash bonus and additional stock options. The Company achieved record revenues and earnings in fiscal 2005. On the basis of performance against the criteria established, the Committee, at the close of fiscal 2005 awarded to Dr. Tsang, Mr. Veronneau and Mr. Melsen the bonuses set forth in the table below under "Summary Compensation Table" and, subsequent to fiscal year end, the options indicated in footnote (3) to the table below under "Options/SAR Grants During 2005 Fiscal Year". During fiscal 2005, the Committee also granted Mr. Melsen options to purchase 25,000 shares (for details on such options see below "Options/SAR Grants During Fiscal 2005). In further recognition of the officers' achievements, the Committee established base salaries for fiscal 2006 as disclosed below under "Employment Contracts and Change in Control Arrangements."

General. The Company provided medical and insurance benefits to its executive officers, which are the same as those generally available to all Company employees. The Company has a profit sharing and savings plan in which all qualified employees, including executive officers, participate subject to statutory limitations on contributions for highly compensated individuals. In fiscal 2005, 2004 and 2003, the Company contributed to the plan an amount equal to approximately 10%, 8% and 4% of gross wages, respectively. One half of the contributions to the plan is in the form of Common Stock of the Company. The amount of perquisites allowed to executive officers, as determined in accordance with rules of the Securities and Exchange Commission, did not exceed 10% of salary in fiscal 2005.

Chief Executive Officer Compensation. Thomas E. Oland served as the Company's Chief Executive Officer in fiscal 2005. His compensation was determined in accordance with the policies described above as applicable to all executive officers. His base salary of \$230,000 in fiscal 2004 was increased to \$242,000 in fiscal 2005. For fiscal 2005 performance he earned, but waived, his annual bonus. In February 1996, the Compensation Committee, in connection with the Board's long-term strategic planning for the Company, adopted a substantial long-term incentive for Mr. Oland in the form of options to purchase an aggregate of 400,000 shares of the Common Stock of the Company at \$4.53 per share, the fair market value on the date of grant. The options are fully vested and will expire on the earlier of (a) as to 268,000 shares one year from the date of termination of employment and as to 132,000 shares three months from the date of termination of employment, or (b) February 1, 2006.

Summary. Aggregate executive compensation increased moderately in fiscal 2005. The Company awarded stock options to officers because the Company achieved record revenues and individual officers achieved certain performance goals. The Compensation Committee intends to continue its policy of paying

relatively moderate base salaries, basing bonuses on specific revenue, profit and performance goals and granting options to provide long-term incentive.

G. Arthur Herbert  
 Howard V. O'Connell  
 Randolph C. Steer, M.D., Ph.D.  
 Robert V. Baumgartner  
 Members of the Compensation Committee

Employment Contracts and Change in Control Arrangements

The Company has formal employment agreements with each of its full-time executive officers with the exception of its President and Chief Executive Officer, with whom the Company has an oral understanding. The agreements provide for base salaries subject to annual review, bonuses as described in the Compensation Committee Report contained in this Proxy Statement, benefits as provided to all employees and severance compensation in the event that the officer's employment is terminated without cause or in connection with a sale or merger of the Company. With the exception of the Chief Financial Officer, severance compensation is dependent upon years of employment with or service to the Company. The Chief Financial Officers severance compensation is equal to the base salary and benefits which would otherwise have been paid under the terms of the employment agreement or the base salary and benefits for twelve months from date of termination, whichever period is longer.

Summary Compensation Table

The following table sets forth certain information regarding compensation paid during each of the Company's last three fiscal years to the Company's President (who serves as Chief Executive Officer) and to the Company's other executive officers whose salary and bonus for fiscal 2005 exceeded \$100,000.

<TABLE>  
 <CAPTION>

Compensation	Long Term					
	Awards					
Payouts	Securities Restricted Underlying					
LTIP Payouts	All Other Compensation	Fiscal Year	Salary(\$)	Bonus(\$)	Stock Options	Restricted Underlying
Name and Principal Position						
Thomas E. Oland, CEO and President	None	2005	242,000	0	None	None
None	22,021					0
None	17,503	2004	230,000	0	None	None
None	8,903	2003	225,000	0	None	None
None	8,903					0
Monica Tsang, Ph.D., Vice President - Research	None	2005	239,400	43,571	None	None
None	22,021					844
None	17,503	2004	228,000	45,600	None	None
None	8,903	2003	221,000	36,841	None	None
None	8,903					1,088

Marcel Veronneau, None	2005	147,000	24,549	None	None	475
Vice President - None	2004	140,000	20,440	None	None	15,505
Hematology Operations None	2003	136,000	22,671	None	None	670
Gregory J. Melsen, None	2005	110,000(3)	22,000	None	None	426
Vice President - N/A	2004	N/A	N/A	N/A	N/A	N/A
Finance and Chief N/A	2003	N/A	N/A	N/A	N/A	N/A
Financial Officer						

</TABLE>  
-----

(1) "None" indicates zero or an amount equal to less than 10% of the total amount of annual salary and bonus reported for the named executive officer.

(2) For each individual the amount reflects Company contributions to Profit Sharing and Savings Plan (as to one-half) and Stock Bonus Plan (as to one-half), the latter in the form of shares of the Company's Common Stock.

(3) January to June 2005.

Options/SAR Grants During 2005 Fiscal Year

The following table provides information related to options granted to the name executive officers during fiscal 2005. The Company has not granted any stock appreciation rights.

<TABLE>  
<CAPTION>

Potential Realizable

Value at Assumed

Annual Rates of Stock

Price Appreciation for

Option Term	Individual Grants						
	5% (\$)	10% (\$)	Name	Number of Securities Underlying Options/SARs Granted (#)	Percent of Total Options/SARs Granted to Employees in Fiscal Year	Exercise or Base Price (\$/Sh)	Expiration Date
-----							
			Thomas E. Oland	0	--	--	--
			Monica Tsang, Ph.D.(3)	1,126(1)	2.9%	40.47	7/08/11
	18,551	43,232					
			Marcel Veronneau (3)	505(1)	1.3%	40.47	7/08/11
	8,320	19,389					
			Gregory J. Melsen (3)	25,000(2)	63.7%	39.53	12/16/14
	621,505	1,575,016					

</TABLE>

- 
- (1) Such option is a non-qualified stock option and became exercisable July 9, 2004.
- (2) Of such 25,000 total, 7,587 were issued as an incentive stock option and 17,413 were issued as a non-qualified stock option. Of the total, 8,000 become exercisable on each of December 17, 2005 and 2006 and 9,000 become exercisable on December 17, 2007, contingent on continued employment.
- (3) Subsequent to fiscal 2005 year end, immediately exercisable non-qualified stock options for the indicated number of shares at an exercise price of \$51.60 per share expiring August 17, 2012 were granted: M. Tsang - 844; M. Veronneau - 475; G. Melsen - 426.

Option/SAR Exercises During 2005 Fiscal Year  
and Fiscal Year End Options/SAR Values

The following table provides information related to options exercised by a named executive officer during the 2005 fiscal year and the number and value of options held by each named executive officer at fiscal year end.

Name	Shares Acquired on Exercise (#)	Value (\$)	Number Of Securities Underlying Unexercised Options/SARs at FY-End (#)		Value of Unexercised In-the-Money Options/SARs at FY-End (\$)	
			Realized	Exercisable/ Unexercisable	Exercisable/ Unexercisable	Exercisable/ Unexercisable
Thomas E. Oland	0	0	400,000/0	16,551,480/0		
Monica Tsang, Ph.D.	6,748	218,807	24,660/8,334	295,143/74,164		
Marcel Veronneau	18,274	691,183	14,544/5,000	173,502/44,495		
Gregory J. Melsen	0	0	0/25,000	0/159,500		

-----

(1) Based on the difference between the \$45.91 per share closing price of the Company's Common Stock as reported by Nasdaq on June 30, 2005 and the option exercise price.

STOCK PERFORMANCE CHART

The following chart compares the cumulative total shareholder return on the Company's Common Stock with the S&P Midcap 400 Index and the S&P 400 Biotechnology Index. The comparison assumes \$100 was invested on June 30, 2000 in the Company's Common Stock and in each of the foregoing indices and assumes reinvestment of dividends.

COMPARISON OF CUMALATIVE FIVE YEAR TOTAL RETURN INDEXED RETURNS

Company/Index	Years Ending				
	June 2001	June 2002	June 2003	June 2004	June 2005
TECHNE CORP	50.00	43.42	46.69	66.85	70.63
S&P MIDCAP 400 INDEX	108.87	103.74	103.00	131.82	150.31
S&P 400 BIOTECHNOLOGY	92.21	45.85	57.15	64.48	60.52

COMPLIANCE WITH SECTION 16(a) OF THE SECURITIES EXCHANGE ACT

Section 16(a) of the Securities Exchange Act of 1934 requires the Company's executive officers and directors, and persons who own more than 10 percent of the Company's Common Stock, to file with the Securities and Exchange Commission initial reports of ownership and reports of changes in ownership of Common Stock and other equity securities of the Company. Officers, directors, and greater than 10 percent shareholders ("Insiders") are required by SEC regulations to furnish the Company with copies of all

Section 16(a) forms they file.

To the Company's knowledge, based on a review of the copies of such reports furnished to the Company, during the fiscal year ended June 30, 2005, all Section 16(a) filing requirements applicable to Insiders were met.

12

#### SHAREHOLDER PROPOSALS

Any appropriate proposal submitted by a shareholder of the Company and intended to be presented at the 2006 Annual Meeting must be received by the Company at its offices by May 22, 2006 to be eligible for inclusion in the Company's Proxy Statement and related Proxy for the 2006 Annual Meeting. For a discussion of policies and procedures related to shareholder recommendations of candidates for director, please see the section on the Nominations and Governance Committee above under Committees and Meetings of the Board.

Also, if a shareholder proposal intended to be presented at the 2006 Annual Meeting but not included in the Company's Proxy Statement and Proxy is received by the Company after August 6, 2006, then management named in the Company's Proxy for the 2006 Annual Meeting will have discretionary authority to vote the shares represented by such proxies on the shareholder proposal, if presented at the meeting, without including information about the proposal in the Company's proxy materials.

#### OTHER BUSINESS

The Board of Directors knows of no other matters to be presented at the meeting. If any other matter does properly come before the meeting, the appointees named in the Proxies will vote the Proxies in accordance with their best judgment.

#### ANNUAL REPORT

A copy of the Company's Annual Report to Shareholders for the fiscal year ended June 30, 2005, including financial statements, accompanies this Notice of Annual Meeting and Proxy Statement. No portion of the Annual Report is incorporated herein or is to be considered proxy-soliciting material.

THE COMPANY WILL FURNISH WITHOUT CHARGE A COPY OF ITS ANNUAL REPORT ON FORM 10-K FOR THE FISCAL YEAR ENDED JUNE 30, 2005, TO ANY SHAREHOLDER OF THE COMPANY UPON WRITTEN REQUEST. REQUESTS SHOULD BE SENT TO PRESIDENT, TECHNE CORPORATION, 614 MCKINLEY PLACE N.E., MINNEAPOLIS, MINNESOTA 55413.

Dated: September 27, 2005  
Minneapolis, Minnesota

13

#### TECHNE CORPORATION

#### PROXY FOR ANNUAL MEETING OF SHAREHOLDERS

THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

The undersigned hereby appoints THOMAS E. OLAND and KATHLEEN BACKES, or either of them acting alone, with full power of substitution, as proxies to represent and vote, as designated below, all shares of Common Stock of Techne Corporation registered in the name of the undersigned, at the Annual Meeting of the Shareholders to be held on Thursday, October 27, 2005 at 3:30 p.m. Central Daylight Time, at the offices of the Company, 614 McKinley Place N.E., Minneapolis, Minnesota, and at all adjournments of such meeting. The undersigned hereby revokes all proxies previously granted with respect to such meeting.

The Nominations and Governance Committee of the Board of Directors recommends that you vote "FOR" the following proposals:

(1) To set the number of Directors at six:

FOR     AGAINST     ABSTAIN

(2) To elect Directors: Nominees: Thomas E. Oland, Roger C. Lucas, Ph.D., Howard V. O'Connell, G. Arthur Herbert, Randolph C. Steer, M.D., Ph.D., and Robert V. Baumgartner.

FOR all Nominees listed above     WITHOUT AUTHORITY  
(except those whose names have    to vote for all nominees  
been written on the line below    listed above

(To withhold authority to vote for any nominee, write that nominee's name on the line below.)

---

(3) Other matters: In their discretion, the appointed proxies are authorized to vote upon such other business as may properly come before the Meeting or any adjournment.

THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED AS DIRECTED OR, IF NO DIRECTION IS GIVEN FOR A PARTICULAR PROPOSAL, WILL BE VOTED FOR SUCH PROPOSAL.

Date \_\_\_\_\_, 2005

---

PLEASE DATE AND SIGN ABOVE exactly as name appears at the left, indicating, where appropriate official position or representative capacity. If stock is held in joint tenancy, each joint owner should sign.